Treatment Strategies for GLILD in Common Variable Immunodeficiency: A Systematic Review
- PMID: 33936030
- PMCID: PMC8086379
- DOI: 10.3389/fimmu.2021.606099
Treatment Strategies for GLILD in Common Variable Immunodeficiency: A Systematic Review
Abstract
Introduction: Besides recurrent infections, a proportion of patients with Common Variable Immunodeficiency Disorders (CVID) may suffer from immune dysregulation such as granulomatous-lymphocytic interstitial lung disease (GLILD). The optimal treatment of this complication is currently unknown. Experienced-based expert opinions have been produced, but a systematic review of published treatment studies is lacking.
Goals: To summarize and synthesize the published literature on the efficacy of treatments for GLILD in CVID.
Methods: We performed a systematic review using the PRISMA guidelines. Papers describing treatment and outcomes in CVID patients with radiographic and/or histologic evidence of GLILD were included. Treatment regimens and outcomes of treatment were summarized.
Results: 6124 papers were identified and 42, reporting information about 233 patients in total, were included for review. These papers described case series or small, uncontrolled studies of monotherapy with glucocorticoids or other immunosuppressants, rituximab monotherapy or rituximab plus azathioprine, abatacept, or hematopoietic stem cell transplantation (HSCT). Treatment response rates varied widely. Cross-study comparisons were complicated because different treatment regimens, follow-up periods, and outcome measures were used. There was a trend towards more frequent GLILD relapses in patients treated with corticosteroid monotherapy when compared to rituximab-containing treatment regimens based on qualitative endpoints. HSCT is a promising alternative to pharmacological treatment of GLILD, because it has the potential to not only contain symptoms, but also to resolve the underlying pathology. However, mortality, especially among immunocompromised patients, is high.
Conclusions: We could not draw definitive conclusions regarding optimal pharmacological treatment for GLILD in CVID from the current literature since quantitative, well-controlled evidence was lacking. While HSCT might be considered a treatment option for GLILD in CVID, the risks related to the procedure are high. Our findings highlight the need for further research with uniform, objective and quantifiable endpoints. This should include international registries with standardized data collection including regular pulmonary function tests (with carbon monoxide-diffusion), uniform high-resolution chest CT radiographic scoring, and uniform treatment regimens, to facilitate comparison of treatment outcomes and ultimately randomized clinical trials.
Keywords: CVID; GLILD; common variable immunodeficiency; granulomatous lymphocytic interstitial lung disease; immunodeficiency; systematic review; treatment.
Copyright © 2021 Lamers, Smits, Leavis, de Bree, Cunningham-Rundles, Dalm, Ho, Hurst, IJspeert, Prevaes, Robinson, van Stigt, Terheggen-Lagro, van de Ven, Warnatz, van de Wijgert and van Montfrans.
Conflict of interest statement
JH and KW co-chair the European Respiratory Society-funded e-GLILDnet Clinical Research Collaboration which is a collaboration with ESID (the European Society for Immunodeficiencies). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer EK declared a past co-authorship with one of the authors CC-R to the handling editor.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8086379/bin/fimmu-12-606099-g001.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8086379/bin/fimmu-12-606099-g002.gif)
Similar articles
-
Rituximab Monotherapy Is Effective as First-Line Treatment for Granulomatous Lymphocytic Interstitial Lung Disease (GLILD) in CVID Patients.J Clin Immunol. 2023 Nov;43(8):2091-2103. doi: 10.1007/s10875-023-01587-4. Epub 2023 Sep 27. J Clin Immunol. 2023. PMID: 37755605 Free PMC article.
-
Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency-Features of CT and 18F-FDG Positron Emission Tomography/CT in Clinically Progressive Disease.Front Immunol. 2021 Jan 26;11:617985. doi: 10.3389/fimmu.2020.617985. eCollection 2020. Front Immunol. 2021. PMID: 33584710 Free PMC article.
-
Rituximab and antimetabolite treatment of granulomatous and lymphocytic interstitial lung disease in common variable immunodeficiency.J Allergy Clin Immunol. 2021 Feb;147(2):704-712.e17. doi: 10.1016/j.jaci.2020.07.021. Epub 2020 Aug 1. J Allergy Clin Immunol. 2021. PMID: 32745555
-
Granulomatous-lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID).Clin Immunol. 2010 Feb;134(2):97-103. doi: 10.1016/j.clim.2009.10.002. Epub 2009 Nov 8. Clin Immunol. 2010. PMID: 19900842 Review.
-
Granulomatous-Lymphocytic Interstitial Lung Disease in 22q11.2 Deletion Syndrome: a Case Report and Literature Review.Curr Allergy Asthma Rep. 2018 Feb 22;18(3):14. doi: 10.1007/s11882-018-0769-7. Curr Allergy Asthma Rep. 2018. PMID: 29470661 Free PMC article. Review.
Cited by
-
STAT expression and TFH1 cells in CVID granulomatosis and sarcoidosis: immunological and histopathological comparisons.Virchows Arch. 2024 Mar;484(3):481-490. doi: 10.1007/s00428-023-03684-6. Epub 2023 Nov 4. Virchows Arch. 2024. PMID: 37924346
-
Common and Uncommon CT Findings in CVID-Related GL-ILD: Correlations with Clinical Parameters, Therapeutic Decisions and Potential Implications in the Differential Diagnosis.J Clin Immunol. 2023 Nov;43(8):1903-1915. doi: 10.1007/s10875-023-01552-1. Epub 2023 Aug 7. J Clin Immunol. 2023. PMID: 37548814 Free PMC article.
-
Granulomatous inflammation in inborn errors of immunity.Front Pediatr. 2023 Feb 20;11:1110115. doi: 10.3389/fped.2023.1110115. eCollection 2023. Front Pediatr. 2023. PMID: 36891233 Free PMC article. Review.
-
Expanding spectrum, intrafamilial diversity, and therapeutic challenges from 15 patients with heterozygous CARD11-associated diseases: A single center experience.Front Immunol. 2022 Nov 3;13:1020927. doi: 10.3389/fimmu.2022.1020927. eCollection 2022. Front Immunol. 2022. PMID: 36405754 Free PMC article.
-
Corticosteroid-induced remission and mycophenolate maintenance therapy in granulomatous lymphocytic interstitial lung disease: long-term, longitudinal change in lung function in a single-centre cohort.ERJ Open Res. 2022 Oct 17;8(4):00024-2022. doi: 10.1183/23120541.00024-2022. eCollection 2022 Oct. ERJ Open Res. 2022. PMID: 36267899 Free PMC article.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical